It depends on who you ask. If you listen to the media, it was a failure. A successful initial public offering has to feel like July 4th fireworks. The stock opens 30% above the set IPO price and then finishes the day up 100%. That’s a newsworthy IPO that (according to the financial commentariat) deserves the uncorking of champagne.
In that kind of IPO, the underwriters, the brokerage firm(s) that brings the deal to the market, have lots to celebrate, too. They’ve used this IPO to butter up their best clients — the ones that bring them the most business.
My investment management firm’s portfolio has a large position in the health-care sector, and with AbbVie’s $63 billion takeover bid for Allergan earlier this week, it’s timely to review why we bought into this sector.
Every time the stock market takes a turn, all sorts of “experts” make all sorts of predictions about what’ll happen next. But who’s right? Can we even tell? Listen to Vitaliy’s value-investor take on this (hint: he doesn’t think much of any predictions).